Tags

Type your tag names separated by a space and hit enter

Current development in the formulations of non-injection administration of paclitaxel.
Int J Pharm. 2018 May 05; 542(1-2):242-252.IJ

Abstract

Paclitaxel (PTX) belongs to a class of taxane anti-tumor drug used for the clinic treatment of breast cancer, ovarian cancer, non-small-cell lung cancer, and so on. PTX has poor water solubility and oral bioavailability. It is generally administered via intravenous (i.v.) infusion. Traditional PTX injectable preparations contain Cremophor-EL and ethanol to improve its solubility, which would result in adverse reactions like severe hypersensitivity, neutropenia, etc. Adverse reactions can be reduced only by complicated pretreatment with glucocorticoid and antihistamines drugs and followed by PTX slow infusion for three hours, which has brought significant inconvenience to the patients. Though, a new-generation PTX formulation, Abraxane, free of Cremophor-EL and ethanol, is still being administrated by frequent i.v. infusions and extremely expensive. Therefore, non-injection administration of PTX is urgently needed to avoid the side effects as well as reduce inconvenience to the patients. Recently, a variety of non-injection drug delivery systems (DDSs) of PTX have been developed. This review aims to discuss the progress of non-injectable administration systems of PTX, including oral administration systems, vaginal administration systems, implantable DDSs, transdermal DDSs and intranasal administration for the future study and clinical applications.

Authors+Show Affiliations

Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan 250012, China.Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan 250012, China.Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan 250012, China.Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan 250012, China.Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan 250012, China.Department of Pharmaceutics, College of Pharmacy, Shandong University, Jinan 250012, China. Electronic address: professorgxzhai@126.com.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

29555439

Citation

Du, Xiyou, et al. "Current Development in the Formulations of Non-injection Administration of Paclitaxel." International Journal of Pharmaceutics, vol. 542, no. 1-2, 2018, pp. 242-252.
Du X, Khan AR, Fu M, et al. Current development in the formulations of non-injection administration of paclitaxel. Int J Pharm. 2018;542(1-2):242-252.
Du, X., Khan, A. R., Fu, M., Ji, J., Yu, A., & Zhai, G. (2018). Current development in the formulations of non-injection administration of paclitaxel. International Journal of Pharmaceutics, 542(1-2), 242-252. https://doi.org/10.1016/j.ijpharm.2018.03.030
Du X, et al. Current Development in the Formulations of Non-injection Administration of Paclitaxel. Int J Pharm. 2018 May 5;542(1-2):242-252. PubMed PMID: 29555439.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current development in the formulations of non-injection administration of paclitaxel. AU - Du,Xiyou, AU - Khan,Abdur Rauf, AU - Fu,Manfei, AU - Ji,Jianbo, AU - Yu,Aihua, AU - Zhai,Guangxi, Y1 - 2018/03/16/ PY - 2018/02/08/received PY - 2018/03/13/revised PY - 2018/03/15/accepted PY - 2018/3/21/pubmed PY - 2018/9/25/medline PY - 2018/3/21/entrez KW - Adverse reactions KW - Nanocarriers KW - Non-injection administration KW - PTX SP - 242 EP - 252 JF - International journal of pharmaceutics JO - Int J Pharm VL - 542 IS - 1-2 N2 - Paclitaxel (PTX) belongs to a class of taxane anti-tumor drug used for the clinic treatment of breast cancer, ovarian cancer, non-small-cell lung cancer, and so on. PTX has poor water solubility and oral bioavailability. It is generally administered via intravenous (i.v.) infusion. Traditional PTX injectable preparations contain Cremophor-EL and ethanol to improve its solubility, which would result in adverse reactions like severe hypersensitivity, neutropenia, etc. Adverse reactions can be reduced only by complicated pretreatment with glucocorticoid and antihistamines drugs and followed by PTX slow infusion for three hours, which has brought significant inconvenience to the patients. Though, a new-generation PTX formulation, Abraxane, free of Cremophor-EL and ethanol, is still being administrated by frequent i.v. infusions and extremely expensive. Therefore, non-injection administration of PTX is urgently needed to avoid the side effects as well as reduce inconvenience to the patients. Recently, a variety of non-injection drug delivery systems (DDSs) of PTX have been developed. This review aims to discuss the progress of non-injectable administration systems of PTX, including oral administration systems, vaginal administration systems, implantable DDSs, transdermal DDSs and intranasal administration for the future study and clinical applications. SN - 1873-3476 UR - https://www.unboundmedicine.com/medline/citation/29555439/Current_development_in_the_formulations_of_non-injection_administration_of_paclitaxel L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378-5173(18)30177-7 DB - PRIME DP - Unbound Medicine ER -